Last $10.00 USD
Change Today 0.00 / 0.00%
Volume 2.8K
WGBS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Open
$10.00
Previous Close
$10.00
Day High
$10.00
Day Low
$10.00
52 Week High
11/25/13 - $35.00
52 Week Low
07/21/14 - $7.00
Market Cap
9.4M
Average Volume 10 Days
718.3
EPS TTM
$-58.13
Shares Outstanding
937.7K
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WAFERGEN BIO-SYSTEMS INC (WGBS)

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample Nanodispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

28 Employees
Last Reported Date: 08/4/14
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $720.0K
Compensation as of Fiscal Year 2013.

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Announces Executive Changes

WaferGen Bio-systems Inc. announced that the company has appointed two seasoned executives to its senior management team, Keith Warner as Chief Operating Officer and Michael Henighan as Chief Financial Officer. Prior to joining WaferGen, Mr. Warner served as a consultant to several life science investment firms since 2009 and was instrumental in assessing new technologies and building early stage companies toward successful M&A transactions. Prior to joining WaferGen, Mr. Henighan was a founder and Chief Financial Officer of Aplegen Inc. since early 2011.

WaferGen Biosystems, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the Full Year for 2014

WaferGen Biosystems, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $1,733,908 against $246,248 a year ago. Operating loss was $3,041,094 against $2,267,865 a year ago. Net loss before provision for income taxes was $1,993,412 against $3,164,206 a year ago. Net loss attributable to common stockholders was $1,993,412 or $2.16 basic and diluted per share against $5,862,322 or $139.79 basic and diluted per share a year ago. The net loss reduction was primarily due to an increase in revenue of $1.5 million, resulting in an increase in gross profit of $806,000, and a $1.9 million improvement in other income and expenses, as a result of reduced interest expense and changes in derivative valuations. These improvements were partially offset by a $1.6 million increase in operating expenses. For the six months, the company reported total revenue of $3,139,421 against $424,735 a year ago. Operating loss was $5,693,475 against $4,560,325 a year ago. Net loss before provision for income taxes was $4,535,927 against $6,942,004 a year ago. Net loss attributable to common stockholders was $4,539,027 or $4.95 basic and diluted per share against $9,850,516 or $234.89 basic and diluted per share a year ago. The company provided revenue guidance for the full year for 2014. Revenue guidance for the full year is in excess of $6 million for 2014, unchanged from its prior guidance.

WaferGen Biosystems, Inc., Q2 2014 Earnings Call, Aug 07, 2014

WaferGen Biosystems, Inc., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $10.00 USD 0.00

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.74 USD +0.16
Fluidigm Corp $26.29 USD -1.76
Luminex Corp $18.59 USD -0.205
NanoString Technologies Inc $11.49 USD +0.02
Sequenom Inc $3.82 USD -0.05
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.